2.14USD
281.59 MUSD
829.25 MUSD
125.67 M
About Halozyme Therapeutics, Inc.
Sector
Industry
CEO
Helen I. Torley
Website
Headquarters
San Diego
Employees (FY)
373
Founded
1998
ISIN
US40637H1095
FIGI
BBG000CZ8W54
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
HALO Daily safe bet pharma swingVRTX I already own, looking to add some more pharma in due time.
HALO has good upside, I calculate +25 pct from 41.16 buy point to dashed line 51.63. 21/50/100 EMA crossover.
17.5 pct ROIC, 5.1 pct free cash flow yield (so so), accelerating revenue growth, buybacks, ROE 105%, Operating margin, 42
Halozyme Therapeutics (HALO) - Frequency Formula Strategy - LongStrategy Overview: The Frequency Formula
Our trading strategy, "The Frequency Formula," is built on cutting-edge Fourier Wave Transform theory. The strategy utilizes four unique indicators: the Frequency Formula Chop Indicator (FF-CI), Frequency Formula Trend Indicator (FF-TI), the Frequency Formu
🟨 2023 WATCHLIST: $HALO2023 WATCHLIST
A series of stocks that i will be monitoring at the beginning of 2023
Here is a new issue from the Biomed Industry.
Relative Strength (IBD): 97
IPO: 2007
Sales acceleration:
Jun-22: 12%
Sep-22: 80%
Funds acceleration:
Jun-22: 708
Sep-22: 743
HALO: Bullish Pennant, not confirmed (+38%)Halo is showing yet again some positive pattern in price action.
Currently building into a bullish pennant (not confirmed) after last week's ascending triangle.
If the price action breaks the top of the flag with volume, we may be in for a 36-37% profit.
Target #1 on confirmed flag = 79.83$
Target
$HALO - Green Line Break and confluence of positive indicatorsMultiple bullish indication on $HALO - see chart annotation for details.
GLB - Green Line Break - breakout of previous ATH and consolidation for >3months.
HALO 2Mtest
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinan
HALO: Ascending Triangle WEEKLY (+70%)Hello all,
Haven't posted anything bullish in quite a while but I believe this one is worth a look.
Thank you to @TORNADOF5 for suggesting it.
HALO seem to have been untouched by the pandemic downtrend, as have many pharmaceutical companies.
So looking at the weekly chart, the price action has bu
W PatternPrice has turned just above the 1.113 for now if that 4th leg of the W is finished.
Short interest is around 8%.
No recommendation.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where HALO is featured.
Frequently Asked Questions
The current price of HALO is 38.64 USD — it has increased by 2.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Halozyme Therapeutics, Inc. stocks are traded under the ticker HALO.
Halozyme Therapeutics, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
HALO stock is 2.54% volatile and has beta coefficient of 1.22. Check out the list of the most volatile stocks — is Halozyme Therapeutics, Inc. there?
One year price forecast for Halozyme Therapeutics, Inc. has a max estimate of 72.00 USD and a min estimate of 39.00 USD.
HALO earnings for the last quarter are 0.75 USD per share, whereas the estimation was 0.71 USD resulting in a 6.21% surprise. The estimated earnings for the next quarter are 0.80 USD per share. See more details about Halozyme Therapeutics, Inc. earnings.
Halozyme Therapeutics, Inc. revenue for the last quarter amounts to 216.03 M USD despite the estimated figure of 216.08 M USD. In the next quarter revenue is expected to reach 231.00 M USD.
Yes, you can track Halozyme Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
HALO stock has fallen by 0.92% compared to the previous week, the month change is a 4.64% fall, over the last year Halozyme Therapeutics, Inc. has showed a 10.91% increase.
HALO net income for the last quarter is 85.39 M USD, while the quarter before that showed 81.84 M USD of net income which accounts for 4.34% change. Track more Halozyme Therapeutics, Inc. financial stats to get the full picture.
Today Halozyme Therapeutics, Inc. has the market capitalization of 4.80 B, it has decreased by 1.29% over the last week.
No, HALO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HALO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Halozyme Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 373.00 employees. See our rating of the largest employees — is Halozyme Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Halozyme Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Halozyme Therapeutics, Inc. stock shows the sell signal. See more of Halozyme Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Halozyme Therapeutics, Inc. future price: according to them, HALO price has a max estimate of 72.00 USD and a min estimate of 39.00 USD. Read a more detailed Halozyme Therapeutics, Inc. forecast: see what analysts think of Halozyme Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Halozyme Therapeutics, Inc. EBITDA is 422.40 M USD, and current EBITDA margin is 50.94%. See more stats in Halozyme Therapeutics, Inc. financial statements.